

**Attachments Table of Contents**

<b>Description</b>	<b>Attachment</b>
Appendix: Collected Excerpts from FDA Qualitative Studies	<b>1</b>
<b><u>Declarations</u></b>	
Declaration of Lamar W. Huckabee (“Huckabee Decl.”)	<b>2</b>
Declaration of Kim Reed (“Reed Decl.”)	<b>3</b>
Declaration of Francis G. Wall (“Wall Decl.”)	<b>4</b>
Declaration of Nooralam Erkin (“Erkin Decl.”)	<b>5</b>
Declaration of Suleman Ismail (“Ismail Decl.”)	<b>6</b>
<b><u>Excerpted Documents</u></b>	
RTI International, Qualitative Study on Cigarettes and Smoking: Knowledge, Beliefs, and Misperceptions (July 2015) (“First Qualitative Study Report”)	<b>7</b>
Siegel+Gale, FDA Graphic Health Warning Image Concept Testing (June 2016) (“Second Qualitative Study Report”)	<b>8</b>
RTI International, Qualitative Study on Consumer Perceptions of Cigarettes Health Warning Images (Apr. 2018) (“Third Qualitative Study Report”)	<b>9</b>
OMB, Notice of Office of Management and Budget Action, Experimental Study on Warning Statements for Cigarette Graphic Health Warnings, Ref. No. 201708-0910-011 (Jan. 29, 2018) (“OMB Notice”)	<b>10</b>

RTI International, Experimental Study on Warning Statements for Cigarette Graphic Health Warnings: Study 1 Report (Apr. 2018) (“First Quantitative Study Report”)	<b>11</b>
RTI International, Experimental Study of Cigarette Warnings: Study 2 Report (May 2019) (“Second Quantitative Study Report”)	<b>12</b>
Final Summary Report: External Letter Peer Review of FDA’s Quantitative Consumer Research on Cigarette Health Warnings Required by the Family Smoking Prevention and Tobacco Control Act (Nov. 19, 2019) (“Peer Review Report”)	<b>13</b>
FDA, Response to External Peer Review of Quantitative Consumer Research on Cigarette Health Warnings Required by the Family Smoking Prevention and Tobacco Control Act (Feb. 4, 2020)	<b>14</b>
FDA, Experimental Study on Warning Statements for Cigarette Graphic Health Warnings: Study 2 Report (Feb. 2020) (“Revised Second Quantitative Study Report”)	<b>15</b>
FDA, Preliminary Regulatory Impact Analysis (Aug. 2019) (“Cost-Benefit Analysis”)	<b>16</b>
FDA, Final Regulatory Impact Analysis, Docket No. FDA-2019-N-3065 (Mar. 2020) (“Final Regulatory Analysis”)	<b>17</b>
<p>Comment Letter of RAI Services Co., Docket No. FDA-2019-N-3065 (Oct. 11, 2019) (“Reynolds Comments”), including:</p> <ul style="list-style-type: none"> <li>• Exhibit C: Statement of Jonathan Klick, Ph.D., J.D. (“Klick Report”)</li> <li>• Exhibit D: Report of Prof. Jan-Benedict Steenkamp (“Steenkamp Report”)</li> <li>• Exhibit E: Samantha Iyengar, Ph.D., <i>NERA Survey: Consumer Perceptions of Cigarette Warning Labels</i> (“Iyengar Report”).</li> <li>• Exhibit F: Report of Dr. John E. Martin, Ph.D. (“Martin Report”)</li> <li>• Exhibit G: Declaration of Lawrence R. Brooks, MD (“Brooks Decl.”)</li> </ul>	<b>18</b>

<ul style="list-style-type: none"> <li>• Exhibit H: Declaration of Jonathan M. Davidorf, MD (“Davidorf Decl.”)</li> <li>• Exhibit I: Declaration of Mark O. Farber, MD (“Farber Decl.”)</li> <li>• Exhibit J: Declaration of Kim R. Jones, MD, Ph.D. (“Jones Decl.”)</li> <li>• Exhibit K: Declaration of Robert Wagmeister, MD (“Wagmeister Decl.”)</li> <li>• Exhibit L: Declaration of Rachael B. Claxton (“Claxton Decl.”)</li> <li>• Exhibit P: Letter from Caitlyn Ozier to FDA with FOIA request (June 14, 2017)</li> </ul>	
Comment Letter of RAI Services Co., Docket No. FDA-2019-N-3065 (Nov. 25, 2019) (“Reynolds Supplemental Comments”)	<b>19</b>
Comment Letter of ITG Brands, Docket No. FDA-2019-N-3065 (Oct. 15, 2019) (“ITG Comments”)	<b>20</b>
Comment Letter of Altria Client Services, Docket No. FDA-2019-N-3065 (Oct. 15, 2019) (“Altria Comments”)	<b>21</b>
Comment Letter of Altria Client Services, Docket No. FDA-2019-N-3065 (Nov. 27, 2019) (“Altria Supplemental Comments”)	<b>22</b>